The US FDA is investigating the first substance for home use to gain control

The FDA regulations mark the first time that the FDA has taken a look at household chemicals.

FluMist is a Nasenspray, which has been developed by AstraZeneca in the USA since 2003 through the Grippeprävention technology. There is a time in Pharmacies and Gesundheitseinrichtungen voor Personen in Alter von 2 bis 49 Jahren nach Rezept verkauft.

Kürzlich has given the Food and Drug Administration (FDA) the freedom to act and thus a similar power for legitimate persons, the impfstoff zu erhalten. This new method is about the self-development during the investigation or the foundation by a nurse for the children’s home.

AstraZeneca plans to sell the Injection Substance to a third-party online pharmacy that will test the approval and prescription before the shipping. If this is not the case, this option can be found at the beginning of the respiratory virus season.

“The large generation of existing grip protection fabrics for self-protection offers a new option for a safe and secure way of seasonal grip protection fabrics, which can provide more protection, protection and protection for individuals and families,” said Dr. Peter Marks, Director of Centers for Biological Evaluation and Research of the FDA.

There is concrete: “An impeachment has been effective for a year, a grip on the impediment, which has made every part of the US population sick and swears complications, certain hospital stays and death traps, leading to.”

Laut Schätzungen de US-Zentrums für Krankheitscontrollle en -prävention (CDC) gab es in der Saison 2023-24 mindestens 35 Millionen gripperelevant Erkrankungen, 400,000 Krankenhausaufenthalte and 25,000 Todesfälle. The CDC is working to implement it for all individuals in 6 months. Allerdings since die Impfquoten sunk in letzter Zeit; In the season the experience is now halved and the childhood of grip protection is over.

FluMist is the only free option for grip protection in the US. A certain version is used, the version of the grippe virus for the Schutz; Integrated variants that are used with inactive viral or proteins, an immune system that trains the virus. AstraZeneca managed, that FluMist offers the same protection with other grippe protection functions.

If the FDA has exercised control over a potential self-protective agent for a year, the investigation into the negotiation for alternative options cannot lead to the self-protection having the implicit meaning of the world of solutions.

Dr. Ashish Jha, dean of the Brown University School of Public Health and coordinator of the White House’s Covid-19 response, said the Bereitstellung is a confident way to see how the supply can be increased. Concretely, 10 to 15 percent of people have a needle phobia, so if the Angebot gets more free options, the impfquotes will be higher.

“I believe that the flow is modest,” he says. The most important thing is that it is a very high brand quality that can be used by AstraZeneca’s marketing activities or other possibilities to use intranasal agents. “I see it as a positive step.”

CNN’s Meg Tirrell is watching this message.

Good health care is separate, an effective way to increase grip so that FluMist exposure becomes a larger part of health care. By FDA medicine can find more people with grip protection fabrics and zugänglicher.

Also read: